Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Research
    • Structural Heart Disease
    • TAVR
    • Therapies
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe

Search form

Home
News You Need to Know Today
News Alert: Weight loss drug semaglutide reduces risk of adverse cardiovascular events
Tuesday, August 8, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

News Alert

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.

READ MORE >
Weekly doses of semaglutide, a GLP-1 receptor originally developed to treat diabetes, could help approximately 93 million U.S. adults lose weight and reduce their risk of adverse cardiovascular events, according to new research published in Cardiovascular Drugs and Therapy. Novo Nordisk sells and markets subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy.
Share on Twitter Share on Facebook Share on Linkedin

Weight loss drug semaglutide reduces risk of adverse cardiovascular events by 20% among overweight, obese patients

Share on Twitter Share on Facebook Share on Linkedin
Weekly doses of semaglutide, a GLP-1 receptor originally developed to treat diabetes, could help approximately 93 million U.S. adults lose weight and reduce their risk of adverse cardiovascular events, according to new research published in Cardiovascular Drugs and Therapy. Novo Nordisk sells and markets subcutaneous treatments of semaglutide 2.4 mg under the brand name Wegovy.
Weekly subcutaneous treatments of semaglutide, originally developed to treat diabetes, are sold and marketed under the brand name Wegovy.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

Interventional Cardiology: IVL's new reimbursement rate | FDA approves 2 RDN systems | Catheter kits recalled
News Alert: FDA approves another renal denervation system for hypertension
Gene-editing therapy for heart patients impresses | Prosthesis-patient mismatch & TAVR: A new perspective
The future of cardiology | A brand new way to evaluate heart risks | CVD deaths on the rise | More from the last week
A warning about TAVR | Trends in care for the tricuspid & mitral valves | Accurate AI | PE funds deal for stroke drug
TAVR or SAVR? | Cardiology groups push for changes that could prevent Medicare cuts | A reimbursement update
Unnecessary stents | Good news for Edwards | TAVR triumphs | Portfolio diet reduces risks | More from the last week

Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page …8
    • Page 9
    • Page 10
    • Page 11
    • Current page 12
    • Page 13
    • Page 14
    • Page 15
    • Page 16 …
    • Next page Next ›
    • Last page Last »
  • Home
  • News
  • Sitemap
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • AI in Healthcare
  • Cardiovascular Business
  • HealthExec
  • Health Imaging
  • Radiology Business
 
© 2024 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup